FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a…
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced…
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty…
Company’s HITRUST-certified Cloud DevOps Managed Services enable new customer to quickly adopt and deploy cloud solutions in a secure, compliant,…
Presentations highlight utility of this advanced hernia reinforcement material for robotic proceduresMALVERN, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- TELA…
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives…
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most…
The World’s Highest Distillery Launches First Ever National Après Day in the U.S. and Celebrates #AprèsAnywhere Campaign Breckenridge Distillery Launches #APRESANYWHERE…
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied…
STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the…